UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015220
Receipt number R000017696
Scientific Title Long-term outcome study of patients with refractory nephrotic syndrome after multicenter, double blind, randomized, placebo-controlled trial of rituximab
Date of disclosure of the study information 2014/09/22
Last modified on 2017/03/25 10:12:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Long-term outcome study of patients with refractory nephrotic syndrome after multicenter, double blind, randomized, placebo-controlled trial of rituximab

Acronym

Long-term outcome study of patients with nephrotic syndrome treated with rituximab

Scientific Title

Long-term outcome study of patients with refractory nephrotic syndrome after multicenter, double blind, randomized, placebo-controlled trial of rituximab

Scientific Title:Acronym

Long-term outcome study of patients with nephrotic syndrome treated with rituximab

Region

Japan


Condition

Condition

refractory nephrotic syndrome

Classification by specialty

Nephrology Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the long-term outcome of patients with refractory nephrotic syndrome after multicenter, double blind, randomized, placebo-controlled trial of rituximab.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

First relapse after rituximab treatment

Key secondary outcomes

1. Administration of immunosuppressive agents after rituximab treatment
2. Re-treatment of rituximab
3. Late onset adverse events after rituximab treatment


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with refractory nephrotic syndrome who was enrolled in the multicenter, double blind, randomized, placebo-controlled trial of rituximab

Key exclusion criteria

Patients who did not participate in the trial

Target sample size

58


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Koichi Kamei

Organization

National Center for Child Health and Development

Division name

Nephrology and Rheumatology

Zip code


Address

2-10-1, Okura, Setagaya-ku, Tokyo

TEL

03-5494-7128

Email

kamei-k@ncchd.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Koichi Kamei

Organization

National Center for Child Health and Development

Division name

Nephrology and Rheumatology

Zip code


Address

2-10-1, Okura, Setagaya-ku, Tokyo

TEL

03-5494-7128

Homepage URL


Email

kamei-k@ncchd.go.jp


Sponsor or person

Institute

Non-Profit Organization Japan Clincal Research Support Unit

Institute

Department

Personal name



Funding Source

Organization

Japan Medical Association Center for Clinical Trials

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 09 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 08 Month 18 Day

Date of IRB


Anticipated trial start date

2014 Year 09 Month 21 Day

Last follow-up date

2016 Year 10 Month 01 Day

Date of closure to data entry

2016 Year 10 Month 01 Day

Date trial data considered complete

2016 Year 12 Month 01 Day

Date analysis concluded

2017 Year 03 Month 01 Day


Other

Other related information

We will soon start retrospective cohort study of enrolled 58 patients.


Management information

Registered date

2014 Year 09 Month 22 Day

Last modified on

2017 Year 03 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017696


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name